tivozanib
Selected indexed studies
- Tivozanib. (, 2012) [PMID:38471024]
- Tivozanib. (, 2006) [PMID:40127365]
- Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 Study. (Lancet, 2024) [PMID:39284329]
_Worker-drafted node — pending editorial review._
Connections
tivozanib is a side effect of
Sources
- Tivozanib. (2012) pubmed
- Tivozanib. (2006) pubmed
- Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 Study. (2024) pubmed
- Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study. (2020) pubmed
- Tivozanib: A New Hope for Treating Renal Cell Carcinoma. (2023) pubmed
- Tivozanib: status of development. (2015) pubmed
- Tivozanib in relapsed or refractory advanced renal cell carcinoma: a focus on US approval. (2022) pubmed
- Tivozanib in renal cell carcinoma: a new approach to previously treated disease. (2020) pubmed
- Current Status of Tivozanib in the Treatment of Patients With Advanced Renal Cell Carcinoma. (2023) pubmed
- Tivozanib for the treatment of renal cell carcinoma: patient selection and perspectives. (2019) pubmed